150 studies found for:    prostate cancer, vaccine therapy
Show Display Options
Rank Status Study
1 Active, not recruiting Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Sargramostim (GM-CSF, Leukine);   Drug: Flutamide (Eulexin);   Biological: PROSTVAC-F/ TRICOM;   Biological: PROSTVAC-V/TRICOM
2 Completed Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant viral vaccine therapy;   Biological: sargramostim
3 Active, not recruiting
Has Results
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine;   Biological: Rilimogene-galvacirepvec
4 Recruiting Vaccine Therapy in Curative Resected Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Biological: Dendritic cell vaccine
5 Withdrawn Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: GVAX prostate cancer vaccine;   Drug: bicalutamide;   Drug: goserelin;   Drug: leuprolide acetate
6 Recruiting Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
7 Unknown  Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
8 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
9 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
10 Unknown  Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: BCG vaccine;   Biological: prostate cancer vaccine ONY-P1;   Other: placebo
11 Unknown  Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: incomplete Freund's adjuvant
12 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: MUC-2-Globo H-KLH conjugate vaccine;   Biological: QS21
13 Completed Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: docetaxel
14 Completed Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: GPI-0100;   Biological: MUC-2-Globo H-KLH conjugate vaccine
15 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: sipuleucel-T;   Biological: Placebo
16 Completed Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: QS21;   Biological: TF(c)-KLH conjugate vaccine;   Biological: Thomsen-Friedenreich antigen;   Biological: keyhole limpet hemocyanin
17 Completed Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: aldesleukin;   Biological: recombinant fowlpox-prostate specific antigen vaccine;   Biological: recombinant vaccinia prostate-specific antigen vaccine;   Biological: recombinant vaccinia-B7.1 vaccine;   Biological: sargramostim;   Drug: nilutamide
18 Completed Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MUC1-KLH vaccine/QS21
19 Completed Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: MUC-2-KLH vaccine;   Biological: QS21
20 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years